Exelixis Inc Revenue, Net (Deprecated 2018-01-31)
Exelixis Inc (EXEL) reported Revenue, Net (Deprecated 2018-01-31) of $7.35 million for the 3-month period ending 2014-12-31, per its 10-K filed 2015-03-02.
Discontinued › Income Statement › Revenue
us-gaap:SalesRevenueNet · last filed 2015-03-02
- Exelixis Inc revenue, net (deprecated 2018-01-31) for the quarter ending 2014-12-31 was $7.35M, a 69.15% increase year-over-year.
- Exelixis Inc revenue, net (deprecated 2018-01-31) for the quarter ending 2014-09-30 was $6.29M, a 15.09% increase year-over-year.
- Exelixis Inc revenue, net (deprecated 2018-01-31) for the quarter ending 2014-06-30 was $6.56M, a 44.65% decline year-over-year.
- Exelixis Inc revenue, net (deprecated 2018-01-31) for the quarter ending 2014-03-31 was $4.91M, a 49.27% decline year-over-year.
| Period end | Revenue, Net (Deprecated 2018-01-31) 3 month | Revenue, Net (Deprecated 2018-01-31) 6 month | Revenue, Net (Deprecated 2018-01-31) 9 month | Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2014-12-31 | $7.35M 10-K · filed 2015-03-02 | $13.64M derived: sum of 2 quarters · filed 2015-03-02 | $20.21M derived: sum of 3 quarters · filed 2015-03-02 | $25.11M derived: sum of 4 quarters · filed 2015-03-02 |
| 2014-09-30 | $6.29M 10-K · filed 2015-03-02 | $12.85M derived: sum of 2 quarters · filed 2015-03-02 | $17.76M 10-Q · filed 2014-11-04 | $22.11M derived: sum of 4 quarters · filed 2015-03-02 |
| 2014-06-30 | $6.56M 10-K · filed 2015-03-02 | $11.47M 10-Q · filed 2014-07-31 | $15.81M derived: sum of 3 quarters · filed 2015-03-02 | $21.28M derived: sum of 4 quarters · filed 2015-03-02 |
| 2014-03-31 | $4.91M 10-K · filed 2015-03-02 | $9.25M derived: sum of 2 quarters · filed 2015-03-02 | $14.72M derived: sum of 3 quarters · filed 2015-03-02 | $26.57M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-12-31 | $4.35M 10-K · filed 2015-03-02 | $9.81M derived: sum of 2 quarters · filed 2015-03-02 | $21.67M derived: sum of 3 quarters · filed 2015-03-02 | $31.34M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-09-30 | $5.47M 10-K · filed 2015-03-02 | $17.32M derived: sum of 2 quarters · filed 2015-03-02 | $26.99M 10-Q · filed 2014-11-04 | $34.80M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $11.86M 10-K · filed 2015-03-02 | $21.52M 10-Q · filed 2014-07-31 | $29.34M derived: sum of 3 quarters · filed 2015-03-02 | $42.65M derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | $9.67M 10-K · filed 2015-03-02 | $17.48M derived: sum of 2 quarters · filed 2015-03-02 | $30.80M derived: sum of 3 quarters · filed 2015-03-02 | $38.61M derived: sum of 4 quarters · filed 2015-03-02 |
| 2012-12-31 | $7.81M 10-K · filed 2014-02-20 | $21.13M derived: sum of 2 quarters · filed 2014-02-20 | $28.94M derived: sum of 3 quarters · filed 2014-02-20 | $47.45M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-09-30 | $13.31M 10-K · filed 2014-02-20 | $21.13M derived: sum of 2 quarters · filed 2014-02-20 | $39.64M derived: sum of 3 quarters · filed 2014-02-20 | $133.94M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | $7.81M 10-K · filed 2014-02-20 | $26.32M derived: sum of 2 quarters · filed 2014-02-20 | $120.63M derived: sum of 3 quarters · filed 2014-02-20 | $248.90M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | $18.51M 10-K · filed 2014-02-20 | $112.82M derived: sum of 2 quarters · filed 2014-02-20 | $241.09M derived: sum of 3 quarters · filed 2014-02-20 | $273.25M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | $94.31M 10-K · filed 2013-02-21 | $222.58M derived: sum of 2 quarters · filed 2013-02-21 | $254.74M derived: sum of 3 quarters · filed 2013-02-21 | $290.64M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-09-30 | $128.27M 10-K · filed 2013-02-21 | $160.43M derived: sum of 2 quarters · filed 2013-02-21 | $196.33M derived: sum of 3 quarters · filed 2013-02-21 | $237.10M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | $32.16M 10-K · filed 2013-02-21 | $68.06M derived: sum of 2 quarters · filed 2013-02-21 | $108.83M derived: sum of 3 quarters · filed 2013-02-21 | $163.31M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | $35.89M 10-K · filed 2013-02-21 | $76.67M derived: sum of 2 quarters · filed 2013-02-21 | $131.14M derived: sum of 3 quarters · filed 2013-02-21 | $178.74M derived: sum of 4 quarters · filed 2013-02-21 |
| 2010-12-31 | $40.78M 10-K · filed 2012-02-22 | $95.25M derived: sum of 2 quarters · filed 2012-02-22 | $142.85M derived: sum of 3 quarters · filed 2012-02-22 | $185.04M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-09-30 | $54.47M 10-K · filed 2012-02-22 | $102.07M derived: sum of 2 quarters · filed 2012-02-22 | $144.27M derived: sum of 3 quarters · filed 2012-02-22 | |
| 2010-06-30 | $47.60M 10-K · filed 2012-02-22 | $89.80M derived: sum of 2 quarters · filed 2012-02-22 | ||
| 2010-03-31 | $42.20M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |